Distinct from prior PCNSL-focused studies (12–15), our data suggest that serum IL-10/IL-6 ratios can predict CNS relapse risk in asymptomatic DLBCL patients, potentially enabling preemptive therapeutic strategies. Here, IL10 is linked to diffuse large B-cell lymphoma.